Join Acceleron for a series of virtual sessions on the development of sotatercept.
 ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌
 
Acceleron Logo
Are you registered for the upcoming 2020 AHA Scientific Sessions?
We are excited to share updates for our investigational agent sotatercept with 3 information sessions, plus a virtual booth page in the AHA Virtual Exhibit Hall, for you to explore.
Join us for these sessions and dive deeper into a review of key clinical trial data:
Abstract Oral Session

Vallerie McLaughlin, MD
Session Title: Dickinson W. Richards Memorial Lecture
Presenter: Vallerie McLaughlin, MD
Cardiopulmonary Best Abstract Award
Abstract Title: Sotatercept Improves Right Ventricular - Pulmonary Arterial Coupling and Right Ventricular Function in the PULSAR Study: A Phase 2, Double-blind, Placebo-controlled, Randomized Study to Compare the Efficacy and Safety of sotatercept versus Placebo when Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
Cardiovascular Seminar

Aaron B. Waxman, MD, PhD
Session Title: Pulmonary Hypertension Clinical Trials with Novel Approaches
Presenter: Aaron B. Waxman, MD, PhD
Presentation Title: SPECTRA and Beyond: Signs of Disease Modification?
Moderated Digital Poster

Sachindra Joshi
Session Title: Targeting Right Ventricular Dysfunction in PAH
Presenter: Sachindra Joshi, PhD
Abstract Title: Sotatercept Analog RAP-011 Inhibits Right Ventricular Remodeling and Restores Function in a Mouse Model of Pressure Overload
Visit our virtual booth page in the AHA Virtual Exhibit Hall to learn more about the work Acceleron is doing in PAH.

Sotatercept is an investigational therapy that is not approved for any use in any country.
This message was sent by Acceleron Pharma Inc.
Acceleron Logo
Acceleron Pharma Inc.
128 Sidney Street
Cambridge, MA 02139
www.acceleronpharma.com
©2020 Acceleron Pharma Inc.
All rights reserved. SO17-102020
Acceleron Pharma Inc.
Privacy Notice
Community Guidelines
Unsubscribe